





UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER OF PATENTS AND TRADEMARKS Washington, D.C. 20231 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/887,832	06/21/2001	Elaine A. Delack	P0136	8018
7:	590 05/13/2002			
Todd N. Hathaway Attorney at Law 119 N. Commercial St., # 620			EXAMINER	
			PRYOR, ALTON NATHANIEL	
Bellingham, W	A 98225-4437		ART UNIT	PAPER NUMBER
			1616	/ 2
		•	DATE MAILED: 05/13/2002	8

Please find below and/or attached an Office communication concerning this application or proceeding.

Office Action Summary

Application No. 09/887,832

Applicant(s)

DeLack

Examiner

Alton Pryor

Art Unit 1616



	The MAILING DATE of this communication appears	on the cover sheet with the correspondence address			
Period f	for Reply				
THE N	ORTENED STATUTORY PERIOD FOR REPLY IS SET MAILING DATE OF THIS COMMUNICATION. It ions of time may be available under the provisions of 37 CFR 1.136 (a). In 1	TO EXPIRE MONTH(S) FROM no event, however, may a reply be timely filed after SIX (6) MONTHS from the			
- If the p - If NO p - Failure - Any re	g date of this communication. period for reply specified above is less than thirty (30) days, a reply within the period for reply is specified above, the maximum statutory period will apply as to reply within the set or extended period for reply will, by statute, cause the ply received by the Office later than three months after the mailing date of the patent term adjustment. See 37 CFR 1.704(b).	and will expire SIX (6) MONTHS from the mailing date of this communication. Be application to become ABANDONED (35 U.S.C. § 133).			
Status 1) 🗆	Page and the communication (a) filed on				
2a) □	This action is FINAL . 2b) 🕱 This action	ion is non-final.			
	•	except for formal matters, prosecution as to the merits is			
	closed in accordance with the practice under Ex parte Quayle, 1935 C.D. 11; 453 O.G. 213.				
	tion of Claims				
4) 💢	Claim(s) 18-24	is/are pending in the application.			
4	a) Of the above, claim(s)	is/are withdrawn from consideration.			
5) 🗆	Claim(s)	is/are allowed.			
6) 🗆	Claim(s)	is/are rejected.			
7) 🗆	Claim(s)	is/are objected to.			
8) 💢	Claims <u>18-24</u>	are subject to restriction and/or election requirement.			
Applica	ition Papers				
9) 🗆	The specification is objected to by the Examiner.				
10)	The drawing(s) filed on is/are	a) \square accepted or b) \square objected to by the Examiner.			
	Applicant may not request that any objection to the d	- · · · · · · · · · · · · · · · · · · ·			
11)	The proposed drawing correction filed on	is: a) \square approved b) \square disapproved by the Examiner.			
If approved, corrected drawings are required in reply to this Office action.					
12)	The oath or declaration is objected to by the Exami	ner.			
Priority under 35 U.S.C. §§ 119 and 120					
	13) Acknowledgement is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).				
a) □ All b) □ Some* c) □ None of:					
	1. Certified copies of the priority documents have been received.				
	2. U Certified copies of the priority documents have				
	 Copies of the certified copies of the priority do application from the International Burea ee the attached detailed Office action for a list of the 				
14) 🗌	Acknowledgement is made of a claim for domestic	•			
a) [7				
15) 🗆	Acknowledgement is made of a claim for domestic	··			
Attachm		French , enest 25 c.c.o. 55 .25 c.c.o2			
_	1) Notice of References Cited (PTO-892) 4) Interview Summary (PTO-413) Paper No(s).				
2) 🔲 No	otice of Draftsperson's Patent Drawing Review (PTO-948)	5) Notice of Informal Patent Application (PTO-152)			
3) Information Disclosure Statement(s) (PTO-1449) Paper No(s) 6) Other:					

Application/Control Number: 09887832 Page 2

Art Unit: 1616

Restriction to one of the following inventions is required under 35 U.S.C. 121:

I. Claims 1,4, drawn to a method of administering histamine N-methyltransferase to a patient, classified in class 435, subclass 15.

- II. Claims 19,20, drawn to a method of administering a histamine H3 antagonist such as thioperamide to a patient, classified in class 514, subclass 326.
- III. Claims 21-24, drawn to a method of administering a monoamine oxidase-A agonist such as reserpine to a patient, classified in class 514, subclass 280.

Inventions I and III and III are unrelated. Inventions are unrelated if it can be shown that they are not disclosed as capable of use together and they have different modes of operation, different functions, or different effects (MPEP § 806.04, MPEP § 808.01). In the instant case the different inventions have different effects.

Because these inventions are distinct for the reasons given above and have acquired a separate status in the art as shown by their different classifications restriction for examination is proper.

This application contains claims directed to the following patentably distinct species of the claimed invention: Numerous compounds that are administered to aging patients.

Applicant is required under 35 U.S.C. 121 to elect a single disclosed species for prosecution on the merits to which the claims shall be restricted if no generic claim is finally held to be allowable. Currently, a method of administering instant compounds to aging patients is generic.

Application/Control Number: 09887832

Art Unit: 1616

Applicant is advised that a reply to this requirement must include an identification of the species that is elected (elect a specific compound to be administered to the patient) consonant with this requirement, and a listing of all claims readable thereon, including any claims subsequently added. An argument that a claim is allowable or that all claims are generic is considered nonresponsive unless accompanied by an election.

Page 3

Upon the allowance of a generic claim, applicant will be entitled to consideration of claims to additional species which are written in dependent form or otherwise include all the limitations of an allowed generic claim as provided by 37 CFR 1.141. If claims are added after the election, applicant must indicate which are readable upon the elected species. MPEP § 809.02(a).

Should applicant traverse on the ground that the species are not patentably distinct, applicant should submit evidence or identify such evidence now of record showing the species to be obvious variants or clearly admit on the record that this is the case. In either instance, if the examiner finds one of the inventions unpatentable over the prior art, the evidence or admission may be used in a rejection under 35 U.S.C. 103(a) of the other invention.

Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a request under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(I).

Application/Control Number: 09887832 Page 4

Art Unit: 1616

A telephone call was made to Attorney Hathaway on 5/10/02 to request an oral election to the above restriction requirement, but did not result in an election being made. Note office action dated 9/28/01 is vacated in light of election requirement above.

Telephonic Inquiry

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Alton Pryor whose telephone number is (703) 308-4691. The examiner can normally be reached on Monday through Friday from 8:00 a.m. to 4:30 p.m.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Jose Dees, can be reached on (703) 308-4628. The fax phone number for this Group is (703) 308-4556.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the Group receptionist whose telephone number is (703) 308-1235.

Alton Pryor

Primary Examiner, AU 1616

Atan M Myn

5/10/02